A Phase 3 interventional study of Cariprazine and Placebo in Bipolar I Disorder, Mania and Depression, sponsored by AbbVie. Completed at 108 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Mania with a site in United States — 5 open to participants now, 5 under way, 4 of them phase 3. Mania · United States.
Among the 94 studies in Mania with a site in United States, this one is the 2nd largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2018, is one of 32 in phase 3, and was the 84th registered.
167 studies on the registry are indexed under Mania; 14 are open to participants now.
Browse Mania studies →5 of the 94 studies in Mania with a site in United States are open now. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Bulgaria and 10 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 17 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, China, Croatia and 8 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 6 more countries
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 20 · Phase 3 33 · Phase 4 27
First in 1991; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 901 is above the median of 89 across 139 interventional studies indexed under Mania.
Median enrollment 83 across the 88 interventional studies, 155 across the 6 observational. Of the 87 that completed or were terminated, 40 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 94 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 6 studies filed under Mania — fewer than ten, so there is no comparison to draw.
1 of the studies in Mania with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
Add it to your calendar (.ics) → With an account.
Among the 94 studies in Mania with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive cariprazine 3.0 mg once daily (QD) for up to 39 weeks.
Drug: Cariprazine
Participants randomized to receive cariprazine 1.5 mg QD for up to 39 weeks.
Drug: Cariprazine
Participants randomized to receive placebo QD for up to 39 weeks.
Drug: Placebo
Participants started on cariprazine 1.5 mg QD, with a target dose of 3.0 mg QD, for up to 16 weeks.
Drug: Cariprazine
Cariprazine capsules, oral administration, once daily
Matching placebo capsules, oral administration, once daily
Time to First Relapse of Any Mood Episode During the Double-Blind Treatment Period
Relapse was defined as the occurrence of any 1 of the following: * Young Mania Rating Score (YMRS) total score ≥ 17 (range 0-60; higher score indicates a worse outcome); * Montgomery Asberg Depression Rating Scale; (MADRS) total score ≥ 20 (range 0-60; higher score indicates more depressive symptoms); * Clinical Global Impression-Improvement scale (CGI-S) ≥ 4 (range from 1 \[normal, not at all ill\] to 7 \[extremely ill\]); * Initiation of additional psychiatric medication; * Psychiatric hospitalization; * Exacerbation of illness as judged by clinical impression of the Investigator. Time to first relapse (days) was calculated as the date of the first relapse - the date of randomization + 1. Participants who did not meet the relapse criteria were considered censored at the time of completion or discontinuation from the Double-Blind Treatment Period (DBTP) of the study. Percentiles (95% Confidence Intervals \[CI\]) are based on Kaplan-Meier estimates.
Time frame: From Week 16 to Week 55
| Milestone | Open Label Treatment Period | Double-Blind Placebo QD | Double-Blind Cariprazine 1.5 mg QD | Double-Blind Cariprazine 3.0 mg QD |
|---|---|---|---|---|
| Started | 896 | 0 | 0 | 0 |
| Completed | 440 | 0 | 0 | 0 |
| Not completed | 456 | 0 | 0 | 0 |
| Withdrew: Adverse event | 67 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 35 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 104 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 55 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 17 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 25 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 2 | 0 | 0 | 0 |
| Withdrew: Failure to meet randomization criteria | 143 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 7 | 0 | 0 | 0 |
| Milestone | Open Label Treatment Period | Double-Blind Placebo QD | Double-Blind Cariprazine 1.5 mg QD | Double-Blind Cariprazine 3.0 mg QD |
|---|---|---|---|---|
| Started | 0 | 145 | 147 | 148 |
| Randomized and treated in double-blind treatment period | 0 | 145 | 144 | 147 |
| Completed | 0 | 79 | 82 | 84 |
| Not completed | 0 | 66 | 65 | 64 |
| Withdrew: Relapse event during double-blind treatment period | 0 | 29 | 25 | 26 |
| Withdrew: Adverse event | 0 | 1 | 5 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 23 | 11 | 14 |
| Withdrew: Lost to follow-up | 0 | 4 | 4 | 9 |
| Withdrew: Protocol violation | 0 | 3 | 8 | 4 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 4 | 4 |
| Withdrew: Other, not specified | 0 | 5 | 8 | 6 |
Relapse was defined as the occurrence of any 1 of the following: * Young Mania Rating Score (YMRS) total score ≥ 17 (range 0-60; higher score indicates a worse outcome); * Montgomery Asberg Depression Rating Scale; (MADRS) total score ≥ 20 (range 0-60; higher score indicates more depressive symptoms); * Clinical Global Impression-Improvement scale (CGI-S) ≥ 4 (range from 1 \[normal, not at all ill\] to 7 \[extremely ill\]); * Initiation of additional psychiatric medication; * Psychiatric hospitalization; * Exacerbation of illness as judged by clinical impression of the Investigator. Time to first relapse (days) was calculated as the date of the first relapse - the date of randomization + 1. Participants who did not meet the relapse criteria were considered censored at the time of completion or discontinuation from the Double-Blind Treatment Period (DBTP) of the study. Percentiles (95% Confidence Intervals \[CI\]) are based on Kaplan-Meier estimates.
| days | Double-Blind Placebo QD | Double-Blind Cariprazine 1.5 mg QD | Double-Blind Cariprazine 3.0 mg QD |
|---|---|---|---|
| 25% percentile | NA (156.0 to NA) | NA (220.0 to NA) | NA (224.0 to NA) |
| 50% percentile | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| 75% percentile | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over Open Label Treatment Period: from enrollment (all-cause mortality [ACM]) or first dose of study drug (adverse events [AEs]) through Week 16 (Day113). Double-Blind Treatment Period (ACM/AEs): From first dose of double-blind treatment up to end of study, Week 59 (Day 414).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label Treatment Period | 1/901 (0.1%) | 19/896 (2.1%) | 256/896 (28.6%) |
| Double-Blind Placebo QD | 1/145 (0.7%) | 5/145 (3.4%) | 27/145 (18.6%) |
| Double-Blind Cariprazine 1.5 mg QD | 0/147 (0%) | 7/144 (4.9%) | 34/144 (23.6%) |
| Double-Blind Cariprazine 3.0 mg QD | 0/148 (0%) | 3/147 (2%) | 34/147 (23.1%) |
| Event | Open Label Treatment Period | Double-Blind Placebo QD | Double-Blind Cariprazine 1.5 mg QD | Double-Blind Cariprazine 3.0 mg QD |
|---|---|---|---|---|
| BIPOLAR I DISORDERPsychiatric disorders | 0/896 | 2/145 | 1/144 | 1/147 |
| APPENDICEAL ABSCESSInfections and infestations | 0/896 | 0/145 | 1/144 | 0/147 |
| APPENDICITIS PERFORATEDInfections and infestations | 0/896 | 0/145 | 1/144 | 0/147 |
| CORONAVIRUS PNEUMONIAInfections and infestations | 0/896 | 0/145 | 1/144 | 0/147 |
| SACRAL RADICULOPATHYNervous system disorders | 0/896 | 0/145 | 1/144 | 0/147 |
| BIPOLAR DISORDERPsychiatric disorders | 3/896 | 0/145 | 1/144 | 1/147 |
| MAJOR DEPRESSIONPsychiatric disorders | 0/896 | 0/145 | 1/144 | 0/147 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/896 | 0/145 | 1/144 | 0/147 |
| FALLInjury, poisoning and procedural complications | 0/896 | 1/145 | 0/144 | 0/147 |
| OVERDOSEInjury, poisoning and procedural complications | 0/896 | 1/145 | 0/144 | 0/147 |
| Event | Open Label Treatment Period | Double-Blind Placebo QD | Double-Blind Cariprazine 1.5 mg QD | Double-Blind Cariprazine 3.0 mg QD |
|---|---|---|---|---|
| AKATHISIANervous system disorders | 105/896 | 2/145 | 6/144 | 2/147 |
| HEADACHENervous system disorders | 79/896 | 15/145 | 14/144 | 10/147 |
| WEIGHT INCREASEDInvestigations | 40/896 | 7/145 | 11/144 | 13/147 |
| INSOMNIAPsychiatric disorders | 77/896 | 5/145 | 9/144 | 6/147 |
| NAUSEAGastrointestinal disorders | 62/896 | 1/145 | 2/144 | 0/147 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 8/896 | 4/145 | 3/144 | 10/147 |
Safety Population: all participants who received at least 1 dose of study medication.
| Age, Customized(Participants) | Open Label Treatment Period |
|---|---|
| < 45 years | 539 |
| ≥ 45 years | 357 |
| Sex: Female, Male(Participants) | Open Label Treatment Period |
|---|---|
| Female | 542 |
| Male | 354 |
| Ethnicity (NIH/OMB)(Participants) | Open Label Treatment Period |
|---|---|
| Hispanic or Latino | 89 |
| Not Hispanic or Latino | 806 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Open Label Treatment Period |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 32 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 258 |
| White | 591 |
| More than one race | 10 |
| Unknown or Not Reported | 0 |
Showing the first 100 of 108 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jun 2018 to primary completion in Sep 2022, 50 months.
Results were first posted in Sep 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine